Lys-102, Lys-114, Lys-145, Lys-181 |
Insoluble overexpressed TDP-43 and TDP-S6 |
HEK-293 |
|
LC-MS/MS |
30 |
Lys-181 |
Overexpressed TDP-43-ΔNLS-Lys-145Q |
QBI293 |
|
TDP-43 IP followed by nano-LC/nanospray/MS/MS |
67 |
Lys-114 |
Endogenous |
HEK-293 |
|
LC-MS/MS |
35 |
Lys-102, Lys-160 |
Endogenous |
MV4-11 |
MG-132 |
Lys-95, Lys-102, Lys-114, Lys-160, Lys-181 |
Endogenous |
HCT116 |
Bortezomib |
LC-MS/MS |
34 |
Lys-102, Lys-114, Lys-121, Lys-140, Lys-145, Lys-160, Lys-176, Lys-181, Lys-263 |
Endogenous |
Myeloma cell lines |
Lys-79 |
Endogenous TDP-43 from Sarko-sylinsoluble human ALS brain |
LC-MS/MS |
13 |